Work for Minerva Neurosciences, Inc?

Claim Your Profile

Minerva Neurosciences, Inc Logo Image

Minerva Neurosciences, Inc

About Minerva Neurosciences, Inc

11-50 Employees
Based in Waltham, Massachusetts

Minerva’s portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia; a potential royalty stream from seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV”.

NASDAQ (See More NASDAQ Companies)
Biotechnology (See More Biotechnology Companies)
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol